Targeting the cGAS-STING Pathway for Cancer Immunotherapy: From Small-Molecule Agonists to Advanced Nanomaterials

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is crucial for innate and adaptive antitumor immunity by sensing DNA and producing cytokines.
• This pathway bridges innate and adaptive immunity, making it a key target for cancer immunotherapy.

Purpose of the Study:

• To review recent advancements in targeting the cGAS-STING pathway for cancer immunotherapy.
• To explore small-molecule agonists and nanomaterial-based therapeutics for cGAS-STING pathway activation.

Main Methods:

• Review of small-molecule agonists (cyclic dinucleotides, non-nucleotides) designed to improve bioavailability and reduce degradation.
• Analysis of nanomaterial-based therapeutics (inorganic and organic carriers) utilizing tumor microenvironment-responsive designs.
• Examination of strategies to synergize cGAS-STING activation with DNA damage, immunogenic cell death, and immune checkpoint blockade.

Main Results:

• Small-molecule agonists like ADU-S100 and MSA-2 show enhanced STING activation and clinical potential.
• Nanotherapeutics effectively convert immunologically 'cold' tumors to 'hot' phenotypes by amplifying cGAS-STING signaling.
• Progress has been made in overcoming limitations of small molecules and developing sophisticated nanoplatforms.

Conclusions:

• Targeting the cGAS-STING pathway holds transformative potential for precision cancer immunotherapy.
• Challenges remain in balancing efficacy with toxicity, optimizing delivery for metastatic disease, and ensuring biocompatibility.
• Future research should focus on smart nanocarriers, biomarker-driven stratification, and combination therapies.